The Predictive Value of Preoperative Negative Prostate Specific Membrane Antigen Positron Emission Tomography Imaging for Lymph Node Metastatic Prostate Cancer

Meijer, Dennie; Barros, Hilda A. de; Leeuwen, Pim J. van; Bodar, Yves J. L.; Poel, Henk G. van der; Donswijk, Maarten L.; Hendrikse, N. Harry; Moorselaar, R. Jeroen A. van; Nieuwenhuijzen, Jakko A.; Oprea-Lager, Daniela E.; Vis, André N.

doi:10.1097/ju.0000000000001592

Cited by 14 publications

(11 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The introduction of novel imaging technique might therefore represent an important step forward, which could help in overcoming limitations of clinical prediction models. As a matter of fact, addition of PSMA PET/CT as the primary staging approach has been shown to improve the accuracy of currently available LNI nomograms [28]. However, the use of PSMA PET/CT is currently not yet recommended for nodal staging in primary setting [1] for two main reasons: (1) limited sensitivity for LNI detection and (2) lack of proven benefit of imaging-based therapeutic decisions and changes in patient management.…”

Section: Random-effects M Odelmentioning

confidence: 99%

Can Negative Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Avoid the Need for Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients? A Systematic Review and Meta-analysis with Backup Histology as Reference Standard

Stabile

Pellegrino

Mazzone

et al. 2022

European Urology Oncology

View full text Add to dashboard Cite

Context: The role of positron emission tomography/computed tomography (PET/ CT) with prostate-specific membrane antigen (PSMA) in the primary staging for patients with prostate cancer (PCa) is still debated. Objective: To analyze published studies reporting the accuracy of PSMA PET/CT for detecting lymph node invasion (LNI) at pelvic lymph node dissection (PLND). Evidence acquisition: A search of PubMed/MEDLINE, Cochrane library's Central, EMBASE and Scopus databases, from inception to May 2021, was conducted. The primary outcome was to evaluate the sensitivity, specificity, positive (PPV) and negative (NPV) predictive values of PSMA PET/CT in detecting LNI on a per-patient level. As a secondary outcome, NPV of PET PSMA was tested on a per-node-level analysis. Detection rates were pooled using random-effect models. Preplanned subgroup analyses tested the diagnostic accuracy after stratification for the preoperative risk group. PPV and NPV variation over LNI prevalence was evaluated. Only studies including extended PLND (ePLND) as the reference standard test were included. Evidence synthesis: Twenty-seven studies, with a total of 2832 participants, were included in quantitative synthesis. The sensitivity, specificity, PPV, and NPV of y These authors contributed equally to this study.

show abstract

Section: Random-effects M Odelmentioning

confidence: 99%

Can Negative Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Avoid the Need for Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients? A Systematic Review and Meta-analysis with Backup Histology as Reference Standard

Stabile

Pellegrino

Mazzone

et al. 2022

European Urology Oncology

View full text Add to dashboard Cite

show abstract

“…A PSMA PET/CT limitation is that a negative PSMA PET/CT cannot rule out lymph node metastases [ 8 , 29 , 30 , 31 ]. Consequently, the ePLND remains the gold standard for primary nodal staging, despite known potential complications, such as lymphocele, lymphedema, and deep venous thrombosis [ 3 ].…”

Section: Psma Pet Diagnosticsmentioning

confidence: 99%

Targeting PSMA Revolutionizes the Role of Nuclear Medicine in Diagnosis and Treatment of Prostate Cancer

Luining

Cysouw

Meijer

et al. 2022

Cancers

Self Cite

View full text Add to dashboard Cite

Targeting the prostate-specific membrane antigen (PSMA) protein has become of great clinical value in prostate cancer (PCa) care. PSMA positron emission tomography/computed tomography (PET/CT) is increasingly used in initial staging and restaging at biochemical recurrence in patients with PCa, where it has shown superior detection rates compared to previous imaging modalities. Apart from targeting PSMA for diagnostic purposes, there is a growing interest in developing ligands to target the PSMA-protein for radioligand therapy (RLT). PSMA-based RLT is a novel treatment that couples a PSMA-antibody to (alpha or beta-emitting) radionuclide, such as Lutetium-177 (177Lu), to deliver high radiation doses to tumor cells locally. Treatment with 177Lu-PSMA RLT has demonstrated a superior overall survival rate within randomized clinical trials as compared to routine clinical care in patients with metastatic castration-resistant prostate cancer (mCRPC). The current review provides an overview of the literature regarding recent developments in nuclear medicine related to PSMA-targeted PET imaging and Theranostics.

show abstract

“…Prostate-specific membrane antigen positron emission tomography/CT has a high negative predictive value (91.6%-96%) when examining patients for nodal involvement in the intermediate-risk group. 3…”

mentioning

confidence: 99%

Letter: Point of View: What Are We Doing? The Incredible Expense and Uncertain Value of Localized Prostate Cancer Diagnostic and Therapeutic “Advances”

Hussain,

Sanchez-Salas

2024

Journal of Urology

View full text Add to dashboard Cite

show abstract

The Predictive Value of Preoperative Negative Prostate Specific Membrane Antigen Positron Emission Tomography Imaging for Lymph Node Metastatic Prostate Cancer

Cited by 14 publications

References 25 publications

Can Negative Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Avoid the Need for Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients? A Systematic Review and Meta-analysis with Backup Histology as Reference Standard

Can Negative Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Avoid the Need for Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients? A Systematic Review and Meta-analysis with Backup Histology as Reference Standard

Targeting PSMA Revolutionizes the Role of Nuclear Medicine in Diagnosis and Treatment of Prostate Cancer

Letter: Point of View: What Are We Doing? The Incredible Expense and Uncertain Value of Localized Prostate Cancer Diagnostic and Therapeutic “Advances”

Contact Info

Product

Resources

About